For patients with suspected interstitial lung disease, the digital biomarker solution Fibresolve offers machine learning capability of diagnosing idiopathic pulmonary fibrosis (IPF) based on assessment of lung computed tomography (CT) scans.
While the diagnosis of lung fibrosis currently may not occur up to two and a half years after initial symptoms, the Food and Drug Administration (FDA) has granted De Novo clearance to Fibresolve, an emerging artificial intelligence (AI)-enabled software that may facilitate earlier diagnosis and timely treatment.
Utilizing machine learning pattern recognition to assess lung computed tomography (CT) scans, Fibresolve may facilitate the diagnosis of lung fibrosis and possibly idiopathic pulmonary fibrosis (IPF), according to Imvaria, the developer of Fibresolve. The company added that Fibresolve can provide subtype classification in cases involving suspected interstitial lung disease (ILD).
The capability of Fibresolve to provide adjunctive qualitative classification of CT imaging findings previously garnered Breakthrough Device Designation from the FDA. Imvaria noted the software also has established CPT billing codes.
“Fibresolve serves as an adjunct to clinicians in assessing patients with suspected lung fibrosis to provide a diagnostic subtype classification, potentially facilitating proper treatments at an earlier stage of the disease process,” said Joshua Reicher, M.D., co-founder and CEO of Imvaria. “The FDA’s authorization of Fibresolve marks a significant milestone, not only for lung fibrosis patients, but also for the advancement of AI-based healthcare technologies.”
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.